Browse by author
Lookup NU author(s): Professor Stephen O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n = 553) or interferon-alpha (IFN) plus cytarabine (n = 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88%-or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML. Leukemia (2009) 23, 1054-1061; doi: 10.1038/leu.2009.38; published online 12 March 2009
Author(s): Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA
Publication type: Article
Publication status: Unknown
Journal: Leukemia
Year: 2009
Volume: 23
Issue: 6
Pages: 1054-1061
ISSN (print): 0887-6924
ISSN (electronic): 1476-5551
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/leu.2009.38
DOI: 10.1038/leu.2009.38
Notes: For the IRIS Investigators
Altmetrics provided by Altmetric
